HeartWare International Inc. (NSDQ:HTWR) won full reimbursement from the French government with publication in an official journal there.
That means French heart patients implanted with the Framingham, Mass.-based company’s ventricular assist device will be covered by that country’s national health care system effective July 4, according to a regulatory filing.
The news sent HTWR shares up a tick, to $77.55, about a 1 percent gain as of roughly 12:45 today.
A report from Swiss investment bank UBS AG placed HeartWare on its list of 44 potential M&A candidates this week, along with erstwhile suitor Thoratec Corp. (NSDQ:THOR) and Abiomed Inc. (NSDQ:ABMD). That union was scuttled two years ago after U.S. anti-trust regulators objected to the deal.
